Internet Stock Review

Is The Market Overvalued? Barron’s Round Table January 2000.

Interesting viewpoints ahead of the market drifting from near 12,000 to 7,000. Equivalent to Dow dropping to near 20,000 today.
dexamethasone, Hepion

Remember President Trump Taking Dexamethasone? Hepion’s (HEPA) CRV431 demonstrated reduced lung inflammation and damage...

Hepion (HEPA) Announces FDA Clearance of IND Application for CRV431 for COVID-19
Hapbee

Jim Kwik and Kevin Harrington Join Hapbee Technologies (HAPB) Board.

Hapbee Announces Additions to Advisory Board December 17, 2020 New Advisors Bring Decades of Entrepreneurial ExperienceWellness...
HAPBEE

Hapbee (HAPB): The Netflix of Feelings

After 15 years, $70 million spent on R&D, and 350,000+ hours of testing, this "Netflix of Feelings" wearable technology is finally...
BioSig, Biotech Stock Review

BioSig (BSGM) Achieves First Commercial Sale of Three PURE EP Systems

Sale Marks Milestone for Company's Commercial expansion at leading Center of Excellence Westport,...
Dr. Marc Hellerstein

Some Scientists Aren’t So Sure A Coronavirus Vaccine Will Come To The Rescue.

Pandemic-weary residents everywhere are holding their breath for the first coronavirus vaccines to be approved by federal regulators. The shots, currently being...
Cyclophilin, Biotech Stock Review

Adding Hepion Pharma (HEPA) $1.73 to Watch List.

Adding Hepion Pharma ($1.73) to Watch List. Oh My. What Did We Find Here? Oh my…and Oh boy....
Internet Stock Review

Newsletter: Institutional Analyst. And Yes, We Have Another Double.

1. Dalrada (DFCO) $0.19. And Yes, We Have Another Double!2. Dyadic (DYAI) $6.40. We're Up 392%, Video Presentation.3....

Dalrada (DFCO) Appoints Gregory L. Remsen To Vice President of Strategic Relationships.

Dalrada Financial Corporation Appoints Gregory L. Remsen To Vice President of Strategic Relationships DALRADA NEWS ARCHIVE

Committed to Win. C-1 and Dyadic’s (DYAI) Drive to Make Vaccines Affordable Worldwide.

Dyadic International, Inc. (NASDAQ: DYAI) – We are a global biotechnology company focused on further improving and leveraging the patented and proprietary...

Latest article

Ardelyx (ARDX) Reports First Quarter 2024 Showing $204 Million in Cash!

When we added Ardelyx (ARDX) to the Watch List in November of 2022, the market cap near $80 million. Now it's...

GeoVax to Provide Corporate Update on Tuesday May 14, 2024.

Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market...

NovaVax (NVAX) Roars Higher, Gaining 225% a $1.2 Billion Increase, at the Blink of...

Sanofi (SNY) Announces Partnership - $500 Million Upfront, plus $700 million in Milestones with NovaVax (NVAX). And some investors say Covid is...